CENTER FOR DRUG EVALUATION AND RESEARCH APPROVAL PACKAGE FOR:

APPLICATION NUMBER

20-668/S-003

Correspondence

DEPARTMENT OF HEALTH & HUMAN SERVICES





Food and Drug Administration Rockville MD 20857

APR -2 2 1999

NDA 20-668/S-003

Astra Pharmaceuticals, L.P. Attention: Eric Couture, Ph.D. 725 Chesterbrook Blvd. Wayne, PA 19087-5677

Dear Dr. Couture:

We acknowledge the receipt of your January 15, 1999 submission containing final printed labeling in response to our October 28, 1999 letter approving your supplemental new drug application for Lexxel (enalapril maleate/felodipine ER) Tablets.

We have reviewed the labeling that you submitted in accordance with our October 28, 1999 letter, and we find it acceptable.

If you have any questions, please contact:

Mr. David Roeder Regulatory Health Project Manager (301) 594-5313

Sincerely yours,

Raymond J. Lipicky, M.D.
Director
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

NDA 20-668/S-003 Page 2

cc:

Archival NDA 20-668 HFD-110/Div. Files HFD-110/D.Roeder

HF-2/Medwatch (with labeling)

HFD-101/ADRA (with labeling)

HFD-40/DDMAC (with labeling)

HFD-95/DDMS (with labeling)

HFD-613/OGD (with labeling)

HFD-735/OPDRA (with labeling)

DISTRICT OFFICE

Drafted by: dlr/April 2, 1999 Initialed by: F Zielinski/4/6/99

K Srinivasachar/4/6/99

W Link/4/6/99 C Duarte/4/6/99 A Karkowsky/4/6/99 N Morgenstern/4/6/99

final:sb/4/7/99

filename: 20668SOO3AR.DOC

ACKNOWLEDGE AND RETAIN (AR)

DIVISION OF CARDIO-RENAL DRUG PRODUCTS FOOD AND DRUG ADMINISTRATION

AUG 19 1998



Woodmont II 1451 Rockville Pike Rockville, MD 20852

This document is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to: CDER, DCRDP (HFD-110); 5600 Fishers Lane; Rockville, MD 20857

Transmitted to FAX Number:

610-695-1828

Attention:

Judy Molt

Company Name:

Astra U.S.A.

Phone:

610-695-1524

Subject:

Labeling comments for NDA 20-668/S-003

Date:

8/19/98

Pages including this sheet:

2

From:

David Roeder

Phone:

301-594-5313

Fax:

301-594-5494

cc:

NDA 20-668 HFD-110

HFD-110/DRoeder

pages redacted from this section of the approval package consisted of draft labeling